1,5-二甲基嘧啶-2(1H)-酮 | 17758-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1,5-二甲基嘧啶-2(1H)-酮
• 英文名称: 1,5-Dimethylpyrimidin-2(1H)-one
• 英文别名: 1,5-dimethylpyrimidin-2-one
• CAS: 17758-24-6
• 化学式: C₆H₈N₂O
• 分子量: 124.14
• InChiKey: INTGUMWWADWLDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-hydrazino-1,5-dimethyl-1H-pyrimidin-2-one 、 氧化银 以70%的产率得到
  参考文献：
  名称：

  UCHYTILOVA V.; HOLY A.; CECH D.; GUT J., COLLECT. CZECH. CHEM. COMMUNS , 1975, 40, NO 8, 2347-2352

  摘要：

  DOI：

文献信息

• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014012360A1

  公开（公告）日：2014-01-23

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新型含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了含有这些含氮杂环化合物的药用可接受的组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
  申请人：Fang Qun Kevin

  公开号：US20110166146A1

  公开（公告）日：2011-07-07

  Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.

  本发明揭示了咪唑并[1,2-a]吡啶类化合物。该发明的化合物是有用的治疗剂，揭示了它们在制药配方中的包含以及在治疗方法中的使用。
• HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
  申请人：Nishino Taito

  公开号：US20120128640A1

  公开（公告）日：2012-05-24

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

  提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物（其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义）、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂，能够扩张血液干细胞和/或造血祖细胞。
• OREXIN RECEPTOR ANTAGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20150126498A1

  公开（公告）日：2015-05-07

  The disclosures herein relate to novel compounds of formula wherein W, X and Y 1 , Y 2 , Y 3 and Y 4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

  本文披露了一种公式化合物，其中W、X和Y1、Y2、Y3和Y4在此定义，并且它们在治疗、预防、改善、控制或降低与促进素受体相关的神经或精神障碍的风险方面的使用。